RBC Capital raised the firm’s price target on uniQure (QURE) to $55 from $24 and keeps an Outperform rating on the shares after the company shared updated 36-month Huntington’s data that showed a benefit that was consistent across multiple endpoints. The firm would be buyers into strength given its belief that uniQure “likely has a drug for a devastating disease that comes with 12x higher risk of committing suicide,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure price target raised to $68 from $48 at Leerink
- Micron reports Q4 beat, Instagram reports 3B MAUs: Morning Buzz
- uniQure price target raised to $65 from $30 at Stifel
- uniQure’s AMT-130 Gene Therapy Shows Promising Results in Huntington’s Disease Trials, Justifying Buy Rating and $70 Price Target
- uniQure has leading candidate in Huntington’s, says H.C. Wainwright